Switch theme
Sign up to access all valuation multiples
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).
1941
n/a
LTM Revenue $1.2B
Last FY EBITDA $109M
$760M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chong Kun Dang Pharma has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Chong Kun Dang Pharma achieved revenue of $1.2B and an EBITDA of $109M.
Chong Kun Dang Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chong Kun Dang Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $387M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $109M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 9% | XXX | XXX | XXX |
| EBIT | $72.7M | XXX | $72.3M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $74.3M | XXX | $79.3M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Chong Kun Dang Pharma's stock price is KRW 86600 (or $63).
Chong Kun Dang Pharma has current market cap of KRW 1.14T (or $829M), and EV of KRW 1.04T (or $760M).
See Chong Kun Dang Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $760M | $829M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Chong Kun Dang Pharma has market cap of $829M and EV of $760M.
Chong Kun Dang Pharma's trades at 0.7x EV/Revenue multiple, and 7.0x EV/EBITDA.
Equity research analysts estimate Chong Kun Dang Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chong Kun Dang Pharma has a P/E ratio of 11.2x.
See valuation multiples for Chong Kun Dang Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $829M | XXX | $829M | XXX | XXX | XXX |
| EV (current) | $760M | XXX | $760M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBIT | 10.4x | XXX | 10.5x | XXX | XXX | XXX |
| EV/Gross Profit | 0.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.2x | XXX | 10.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -576.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChong Kun Dang Pharma's last 12 month revenue growth is 6%
Chong Kun Dang Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Chong Kun Dang Pharma's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chong Kun Dang Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Chong Kun Dang Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chong Kun Dang Pharma acquired XXX companies to date.
Last acquisition by Chong Kun Dang Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Chong Kun Dang Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Chong Kun Dang Pharma founded? | Chong Kun Dang Pharma was founded in 1941. |
| Where is Chong Kun Dang Pharma headquartered? | Chong Kun Dang Pharma is headquartered in South Korea. |
| Who is the CEO of Chong Kun Dang Pharma? | Chong Kun Dang Pharma's CEO is Mr. Young-joo Kim. |
| Is Chong Kun Dang Pharma publicy listed? | Yes, Chong Kun Dang Pharma is a public company listed on KRX. |
| What is the stock symbol of Chong Kun Dang Pharma? | Chong Kun Dang Pharma trades under 185750 ticker. |
| When did Chong Kun Dang Pharma go public? | Chong Kun Dang Pharma went public in 2013. |
| Who are competitors of Chong Kun Dang Pharma? | Similar companies to Chong Kun Dang Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Chong Kun Dang Pharma? | Chong Kun Dang Pharma's current market cap is $829M |
| What is the current revenue of Chong Kun Dang Pharma? | Chong Kun Dang Pharma's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Chong Kun Dang Pharma? | Chong Kun Dang Pharma revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Chong Kun Dang Pharma? | Current revenue multiple of Chong Kun Dang Pharma is 0.6x. |
| Is Chong Kun Dang Pharma profitable? | Yes, Chong Kun Dang Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
